Everest Medicines lands $310m Series C
Everest Medicines, a biopharmaceutical company, has raised $310 million in Series C financing.
Everest Medicines, a biopharmaceutical company, has raised $310 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination